MTX 652
Alternative Names: DMX-652; MTX-652Latest Information Update: 23 Jul 2026
At a glance
- Originator MISSION Therapeutics
- Class Antifibrotics; Heart failure therapies; Small molecules; Urologics
- Mechanism of Action Usp30 protein inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Acute kidney injury; Heart failure; Idiopathic pulmonary fibrosis; Muscular dystrophies; Renal failure
Most Recent Events
- 23 Jul 2026 MTX 652 is still in phase-I development in Acute kidney injury(In volunteers) in United Kingdom (PO)
- 17 Jul 2026 Mission Therapeutics acquire MTX 652 from Dimerix Biosciences
- 28 Jun 2025 No recent reports of development identified for phase-I development in Acute kidney injury(In volunteers) in United Kingdom (PO)